NCT04001413View on ClinicalTrials.gov

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 17, 2019

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
HPV Positive Oropharyngeal Squamous Cell CarcinomaOropharynx CancerHPV-Related Carcinoma
Interventions
DRUG

MEDI0457

MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study

DRUG

Durvalumab

Durvalumab is an investigational drug in this study.

Trial Locations (4)

10029

Mount Sinai School of Medicine, The Tisch Cancer Institute, New York

Mount Sinai School of Medicine, New York

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER